This statistic shows the enterprise value of leading pure players in rare oncology disease therapeutics worldwide as of 2017. As of that year, the value of Celgene which is specialized on multiple meloma therapeutics was around 113 billion U.S. dollars.
Enterprise value of leading pure players in oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*
Profit from the additional features of your individual account
Currently, you are using a shared account. To use individual functions (e.g., mark statistics as favourites, set
statistic alerts) please log in with your personal account.
If you are an admin, please authenticate by logging in again.
Learn more about how Statista can support your business.
Torreya Partners. (October 27, 2017). Enterprise value of leading pure players in oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)* [Graph]. In Statista. Retrieved December 21, 2024, from https://www.statista.com/statistics/784362/oncology-rare-disease-therapeutics-leading-players-enterprise-value-worldwide/
Torreya Partners. "Enterprise value of leading pure players in oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*." Chart. October 27, 2017. Statista. Accessed December 21, 2024. https://www.statista.com/statistics/784362/oncology-rare-disease-therapeutics-leading-players-enterprise-value-worldwide/
Torreya Partners. (2017). Enterprise value of leading pure players in oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)*. Statista. Statista Inc.. Accessed: December 21, 2024. https://www.statista.com/statistics/784362/oncology-rare-disease-therapeutics-leading-players-enterprise-value-worldwide/
Torreya Partners. "Enterprise Value of Leading Pure Players in Oncology Rare Disease Therapeutics Worldwide as of 2017 (in Million U.S. Dollars)*." Statista, Statista Inc., 27 Oct 2017, https://www.statista.com/statistics/784362/oncology-rare-disease-therapeutics-leading-players-enterprise-value-worldwide/
Torreya Partners, Enterprise value of leading pure players in oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)* Statista, https://www.statista.com/statistics/784362/oncology-rare-disease-therapeutics-leading-players-enterprise-value-worldwide/ (last visited December 21, 2024)
Enterprise value of leading pure players in oncology rare disease therapeutics worldwide as of 2017 (in million U.S. dollars)* [Graph], Torreya Partners, October 27, 2017. [Online]. Available: https://www.statista.com/statistics/784362/oncology-rare-disease-therapeutics-leading-players-enterprise-value-worldwide/
